Alemtuzumab Treatment Can Affect CD52 Positive As Well As CD52 Negative GPI-Deficient, Sezary Cells Allowing Long-Teem Disease Control

Author(s):
Halkes, C.J.M.; Jedema, I.; Egmond, H.M. van; Fits, L. van der; Falkenburg, J.H.F.; Vermeer, M.H.
Published
2011
Publication type
Article / Letter to editor
Date issued
2011-11-18
Language
English
Is part of
Blood (2011), Vol. 118, no. 21, p. 1066-1067
hdl
1887/98976